What are the available treatment options for metachromatic leukodystrophy and what parameters should be monitored?

Treatment Options for Metachromatic Leukodystrophy

For early-onset MLD (late infantile and early juvenile forms), hematopoietic stem cell gene therapy (HSPC-GT) should be administered before symptom onset or at very early stages of neurological involvement, while late-onset MLD (late juvenile and adult forms) should be treated with hematopoietic stem cell transplantation (HSCT) when patients are presymptomatic or minimally symptomatic. 1, 2

Treatment Algorithm by Disease Subtype

Late Infantile MLD

• No specific therapy exists for symptomatic late infantile MLD 3
• Treatment is restricted to palliative and supportive care including prevention of secondary complications 3
• HSCT is completely ineffective and not recommended even at presymptomatic stages 3
• Gene therapy (HSPC-GT/atidarsagene autotemcel) is the treatment of choice for presymptomatic or very early symptomatic patients where available 4, 1, 2

Juvenile and Adult MLD

• HSCT is the established therapeutic option for juvenile and adult forms when performed before clinical symptom onset 3
• HSCT can stabilize cerebral demyelination and arrest or slow disease progression in later-onset forms 3
• Critical limitation: HSCT does not arrest peripheral nervous system disease progression, and patients develop severe peripheral neuropathy-related motor deficits years after transplantation 3

Treatment Timing Considerations

The type of presenting symptoms influences treatment decisions 5:

• Patients with cognitive presentation have slower or no motor decline
• Patients with mixed motor and cognitive presentation have more rapid progression
• Treatment is most effective when administered before disease onset 5

Monitoring Parameters

Pre-Treatment Assessment (Mandatory)

Diagnostic confirmation 3:

• Urinary sulfatide analysis
• ARSA gene sequencing (essential due to high frequency of pseudodeficiency alleles)

Baseline evaluations 4, 1:

• Standardized neurological assessment
• Developmental/cognitive testing
• Brain MRI with severity scoring
• Multidisciplinary eligibility evaluation

Treatment Phase Monitoring

For patients undergoing HSPC-GT 4:

• Stem cell collection monitoring
• Busulfan conditioning surveillance
• Acute complication monitoring
• Supportive care parameters

Post-Treatment Long-Term Follow-Up (Minimum 15 Years)

Neurological surveillance 3, 4:

• Regular neurologist evaluations at defined intervals
• Metabolic physician follow-up
• Motor function assessment
• Peripheral neuropathy monitoring (especially post-HSCT patients)

Developmental/Cognitive monitoring 4, 1:

• Standardized developmental assessments
• Cognitive function testing
• Educational/adaptive functioning evaluation

Imaging surveillance 3, 4:

• Periodic brain MRI to monitor CNS demyelination status
• MRI severity scoring for response to therapy
• Grey and white matter volume assessment 6

Laboratory monitoring 4, 6:

• ASA enzyme activity (should normalize post-HSCT) 6
• Urinary sulfatide levels
• Systematic biobanking for long-term safety data

Critical Pitfalls to Avoid

1. Pseudodeficiency alleles: A homozygous pseudodeficient genotype is approximately 400 times more common than true MLD, requiring both enzyme testing AND gene sequencing for diagnosis 3

2. Genotype-phenotype limitations: While excellent for patients homozygous for null alleles, patients with R alleles show considerable phenotypic variability, making reliable prognostication impossible in these cases 3

3. HSCT peripheral neuropathy: Even successful HSCT patients develop severe peripheral neuropathy-related motor deficits years after transplantation—this must be discussed during consent 3

4. Treatment window: Both HSCT and gene therapy are only effective when administered presymptomatically or at very early symptomatic stages 3, 4, 1, 2

Emerging Considerations

Newborn screening is becoming available in several countries 2, 5, creating new challenges for:

• Timing of treatment initiation in screen-positive infants
• Distinguishing true MLD from pseudodeficiency
• Treatment eligibility decisions

International treatment eligibility panels now exist to provide consensus-based recommendations for complex cases, particularly regarding treatment timing and modality selection 7